Acute lymphoblastic leukemia in children

Current Opinion in Oncology

Volumn 12, Issue 1, 2000, Pages 3-12

  Pui, Ching Hon ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ANTIMETABOLITE; ASPARAGINASE; CYTARABINE; DEXAMETHASONE; FOLINIC ACID; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NELARABINE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE DISEASE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; GENETIC POLYMORPHISM; HUMAN; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SKULL IRRADIATION; THROMBOSIS;

ANTINEOPLASTIC AGENTS; CHILD; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT;

EID: 0034518313     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200001000-00002     Document Type: Review

References (136)

1. Intensive BFM chemotherapy for childhood ALL: Interim analysis of the AIEOP-ALL 91 study
2. Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: Results of trial ALL-BFM90
3. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies
4. Improvement in CNS protection treatment in non-high-risk childhood acute lymphoblastic leukemia: Report from the Japanese Children's Cancer and Leukemia Study Group
5. Results of the Dana-Farber Cancer Institute (DFCI) consortium protocol 91-01 for children with acute lymphoblastic leukemia (ALL)
6. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BGM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group protocol ALL-7 (1988-91)
7. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: Differences in outcome are poorly explained by the most significant prognostic variables
8. Treatment results in childhood acute lymphoblastic leukemia with a modified ALL·BFM '90 protocol: Lack of improvement in high-risk group
9. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: The Nordic experience of 2648 patients diagnosed between 1981 and 1996
10. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study
11. Early intensification of intrathecal chemotherapy virtually eliminates central nevous system relapse in children with acute lymphoblastic leukemia
12. Analysis of the immunophenotype of children treated on the Medical Research Council Unitd Kingdom Acute Lymphoblastic Leukaemia Trail XI (MRC UKALLXI)
13. Acute lymphoblastic leukemia
14. Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: Relationship with in vitro drug resistance
15. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia
16. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies
17. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: A report from the MRC Paediatric and Adult Working Parties
18. Sex differences in prognosis for children with acute lymphoblastic leukemia
19. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: A report from the Children's Cancer Group
20. A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia
21. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia
22. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
23. Hematologic malignancies with t(4;11)(q21;q23)-a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases
24. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation
25. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
26. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: A distinct biological entity with a marked propensity to undergo apoptosis
27. The role of TEL fusion genes in pediatric leukemias
28. Aberrant expression of KOR-SA3544 antigen in childhood acute lymphoblastic leukemia predicts TEL-AML1 negativity
29. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: A Pediatric Oncology Group study
30. An investigation of the t(12;21) rearrangement in children with B-precursor acute lymphoblastic leukaemia using cytogenetic and molecular methods
31. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia
32. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup
33. TEL/AML1 positivity in childhood ALL: Average or better prognosis?
34. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia
35. TEL·AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia
36. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia
37. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse
38. Bcl-2 protein and apoptosis in pediatric acute lymphoblastic leukemia
39. Mutational analysis of Bax and Bcl-2 in childhood acute lymphoblastic leukaemia
40. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia
41. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia
42. Enhanced expression of p16ink4a is associated with a poor prognosis in childhood acute lymphoblastic leukemia
43. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
44. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs
45. Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia
46. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia
47. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
48. Induction failure in acute lymphoblastic leukemia of childhood
49. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
50. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia
51. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: Detection in remission marrow predicts outcome
52. Flow cytometric analysis of normal B cell differentiation: A frame of reference for the detection of minimal residual disease in precursor-B-ALL
53. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
54. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
55. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome
56. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia
57. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia
58. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia
59. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric Oncology Group Study
60. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia
61. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia
62. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: A Pediatric Oncology Group pilot study
63. Meeting report: International Childhood ALL Workshop: Memphis, TN, 3-4 December 1997
64. Improved survival with early intensification: Combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI
65. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
66. Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL)
67. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization
68. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study
69. Consolidation therapy with antimetabolite-based therapy in standard risk acute lymphocytic leukemia of childhood: A Pediatric Oncology Group Study
70. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia
71. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia
72. Anti-asparaginase (ASP) antibodies do not impact event-free survial (EFS) in children with acute lymphoblastic leukemia (ALL)
73. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia
74. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: A report from the Taiwan Pediatric Oncology Group
75. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia
76. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols
77. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group phase III trial
78. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
79. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy
80. Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation
81. Role of folylpolyglutamate synthetase and folylglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia
82. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
83. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint Children's Cancer Group and Pediatric Oncology Branch study
84. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine
85. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group
86. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: Randomized controlled trial from the Children's Cancer Group
87. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: Report from the Japanese Children's Cancer and Leukemia Study Group
88. Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials
89. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study
90. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group
91. Intensified therapy for infants with acute lymphoblastic leukemia
92. High risk infant ALL-improved survival with intensive chemotherapy
93. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
94. Acute lymphoblastic leukemia in infants
95. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants
96. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: A Children's Cancer Group report
97. Down's syndrome in childhood acute lymphoblastic leukemia: Clinical characteristics and treatment outcome in four consecutive BFM trials
98. Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response
99. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
100. Factors associated with outcome after cord blood transplantation in children with acute leukemia
101. Outcome of acute lymphoblastic leukaemia in Danish children after allogeneic bone marrow transplantation. Superior survival following transplantation with matched unrelated donor grafts
102. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings
103. Developments in allogeneic peripheral blood progenitor cell transplantation
104. Stem cell transplantation in acute leukemia
105. Haemopoietic stem cell transplantation from unrelated donors
106. Second malignancies in patients treated for childhood acute lymphoblastic leukemia
107. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital
108. High incidence of secondary brain tumours after radiotherapy and antimetabolites
109. A comparative study of the long-term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation
110. Bone mass after treatment for acute lymphoblastic leukemia in childhood
111. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia
112. Growth and endocrinological disorders up to 21 years after treatment for acute lymphoblastic leukemia in childhood
113. Height and weight pattern up to 20 years after treatment for acute lymphoblastic leukaemia
114. Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood
115. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia
116. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study
117. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies
118. Impact of age and cranial irradiation on radiographic skeletal pathology in children with acute lymphoblastic leukemia
119. Effects of a third intensification block of chemotherapy on bone and collagen turnover, insulin-like growth factor I, its binding proteins and short-term growth in children with acute lymphoblastic leukaemia
120. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood
121. Osteonecrosis during the treatment of childhood acute lymphoblastic leukemia: A prospective MRI study
122. Aseptic osteonecrosis in children with acute lymphoblastic leukemia
123. Avascular necrosis of bone - A complication of aggressive therapy for acute lymphoblastic leukemia
124. Factor V Leiden and other hypercoagulable state mutations are not associated with osteonecrosis during or after treatment for pediatric malignancy
125. Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia
126. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors
127. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia
128. Intolerance to mercaptopurine therapy related to heterozygosity at the thiopurine methyltransferase gene locus
129. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
130. Polymorphism of the thiopurine S-methyltransferase gene in African Americans
131. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia
132. Association of CYP3A4 genotype with treatment-related leukemia
133. 609C→T polymorphism in the NAD(P)H: Quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
134. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms
135. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
136. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia